Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Inclusion Criteria: * Histologically confirmed, unresectable advanced or metastatic biliary tract carcinoma (BTC) including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma, and ampulla of Vater (AoV) carcinoma * Participants with unresectable or metastatic BTC * A World Health Organisation Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) of 0 to 2 * At least one lesion that qualifies as a Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) target lesion at baseline * Adequate organ and bone marrow function * Body weight of \> 30 kg * Negative pregnancy test (serum) for women of childbearing potential * Female participants must be one year post-menopausal (amenorrhoeic for 12 months without an alternative medical cause) * Male and female participants and their partners must be surgically sterile or on their chosen method of birth control as per the protocol. Exclusion Criteria: * Any evidence of diseases such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active interstitial lung disease/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations, history of uncontrolled or symptomatic cardiac disease, and history of allogenic organ transplant * Active or prior documented autoimmune or inflammatory disorders * History of another primary malignancy, except for malignancy tre…